Press "Enter" to skip to content

New patent for Sanofi-aventis Us drug SOLIQUA 100/33

0
Copyright © DrugPatentWatch. Originally published at New patent for Sanofi-aventis Us drug SOLIQUA 100/33

Annual Drug Patent Expirations for SOLIQUA+100%2F33
Annual Drug Patent Expirations for SOLIQUA+100%2F33

Soliqua 100/33 is a drug marketed by Sanofi-aventis Us and is included in one NDA. It is available from one supplier. There are twenty-five patents protecting this drug.

Drug patent litigation for SOLIQUA 100/33.

This drug has three hundred and forty-seven patent family members in forty-nine countries.

The generic ingredient in SOLIQUA 100/33 is insulin glargine; lixisenatide. One supplier is listed for this compound. Additional details are available on the insulin glargine; lixisenatide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent for Sanofi-aventis Us drug SOLIQUA 100/33
    Do NOT follow this link or you will be banned from the site!